Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.46
  • Today's Change-0.46 / -4.21%
  • Shares traded21.75k
  • 1 Year change+53.37%
  • Beta1.7993
Data delayed at least 15 minutes, as of Mar 03 2026 20:44 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

  • Revenue in USD (TTM)204.17m
  • Net income in USD19.63m
  • Incorporated1999
  • Employees700.00
  • Location
    Valneva SE6, Rue Alain BombardSAINT-HERBLAIN 44800FranceFRA
  • Phone+33 228073710
  • Fax+33 144217078
  • Websitehttps://valneva.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arbutus Biopharma Corp14.61m-42.28m898.15m44.00--11.58--61.49-0.2219-0.22190.07640.40320.1227--11.62331,954.50-35.50-44.03-39.50-49.46-----289.45-433.59----0.0454---65.980.52684.02---20.93--
Xencor Inc125.58m-91.92m902.07m260.00--1.39--7.18-1.24-1.241.698.840.1374--2.79482,984.60-10.08-9.90-11.18-10.89-----73.37-51.10----0.1585--13.650.465460.48---25.55--
CytomX Therapeutics Inc113.63m28.02m904.79m119.0013.268.2130.887.960.40270.40270.97330.65060.7646--45.63954,882.4018.85-15.5840.91-26.48----24.66-50.39----0.00--36.4519.165,700.88---38.41--
BIOAGE Labs Inc5.92m-75.79m906.34m62.00--2.81--153.18-2.04-2.040.15947.740.0184----95,435.48-23.59---25.31-------1,280.90------0.0147-------11.36------
ARS Pharmaceuticals Inc142.77m-80.04m906.44m162.00--6.14--6.35-0.9012-0.90121.381.490.48363.567.67921,109.70-27.11-14.27-30.61-14.8289.40---56.06-224.856.51--0.3946--297,063.30--114.71--42.45--
Maravai Lifesciences Holdings Inc185.74m-130.77m928.01m435.00--4.35--5.00-0.9059-0.90591.290.82960.20883.355.80426,995.40-25.954.29-36.495.5618.3068.51-124.2413.715.69-7.540.46420.00-28.34-8.159.72---12.34--
MannKind Corp348.97m6.70m935.08m592.00157.17--49.262.680.01930.01931.12-0.16580.58852.456.56589,469.601.13-7.581.44-9.7177.8070.191.92-14.561.501.311.09--22.2339.89-78.75---0.9285--
Valneva SE (ADR)204.17m19.63m942.72m700.00------4.62-0.8765-0.8765----------293,773.00--------9.62--9.62----1.84----10.32--87.93------
Cullinan Therapeutics Inc0.00-216.81m944.63m111.00--2.09-----3.68-3.680.007.640.00----0.00-38.12-16.54-40.13-17.34-------1,797.10----0.00-------9.28------
Personalis Inc69.65m-81.27m947.96m260.00--3.55--13.61-0.9088-0.90880.78052.550.23058.925.72267,876.90-26.89-30.49-30.46-34.8122.6527.97-116.69-118.806.61--0.0197---17.69-2.400.0172--6.77--
Arrivent Biopharma Inc0.00-151.40m956.90m52.00--3.10-----4.24-4.240.007.470.00----0.00-48.90---51.98--------------0.00-------16.09------
CareDx Inc379.81m-21.35m960.05m761.00--3.15--2.53-0.3943-0.39437.095.950.845.337.08499,086.70-4.72-10.84-5.89-12.9467.5566.23-5.62-16.522.56--0.00--13.7914.59-140.64---8.66--
Fortrea Holdings Inc2.72bn-986.20m987.36m14.30k--1.74--0.3626-10.90-10.9029.666.050.8653--4.36190,447.50-31.33-5.20-44.50-6.5218.5020.89-36.21-7.39---0.25870.6514--1.001.09-263.24--0.9806--
Geron Corp183.88m-85.78m989.45m229.00--4.43--5.38-0.1287-0.12870.27590.35030.3159-------14.74-38.49-17.83-48.9897.42---46.65-267.01---3.70----138.83273.4950.86------
GH Research PLC0.00-42.92m993.09m50.00--3.41-----0.7313-0.73130.004.700.00----0.00-17.11-12.39-17.83-12.66------------0.002-------9.48------
Data as of Mar 03 2026. Currency figures normalised to Valneva SE's reporting currency: US Dollar USD

Institutional shareholders

0.69%Per cent of shares held by top holders
HolderShares% Held
General American Investors Co., Inc. (Investment Management)as of 31 Dec 2025354.36k0.41%
Wells Fargo Clearing Services LLCas of 31 Dec 2025123.46k0.14%
Morgan Stanley & Co. International Plcas of 31 Dec 202532.26k0.04%
Ironwood Investment Management LLCas of 31 Dec 202525.14k0.03%
Citadel Securities LLCas of 31 Dec 202523.49k0.03%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 202510.70k0.01%
XTX Markets LLCas of 31 Dec 202510.63k0.01%
JPMorgan Securities LLC (Investment Management)as of 31 Dec 20259.40k0.01%
China Universal Asset Management Co., Ltd.as of 31 Dec 20255.00k0.01%
GAMMA Investing LLCas of 31 Dec 20251.86k0.00%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.